Interview with Warren Chen, Country Manager, Celgene Taiwan
Could you please give our readers an overview of the importance of Taiwan for Celgene in a regional and a global context? What is attractive in Taiwan for Celgene? Celgene…
Address:
Tel: 886-2-2655-8133
In view of the need for an inter-agency task to carry out the promotion of the biotechnology and pharmaceutical high-tech industries, in November 1995 the Executive Yuan approved the key points for establishing the Biotechnology and Pharmaceutical Industries Program Office (BPIPO, MOEA). In February 1996 the BPIPO was formerly established to implement and promote the biotechnology industry’s development policy and act as a bridge for communication, coordination and integration among agencies. In December 2001, The Executive Yuan’s One-Stop-Service Office for the Biotechnology Industry was established under the BPIPO, with the office being responsible for the integration and coordination of local organizations involved in the various biotech-related approval and application processes, to build up a sound development environment for the biotech industry. The Director of the Industrial Development Bureau, MOEA acted as convener of the Program Office and formed a committee including the heads of the Executive Yuan’s Department of Health; Environmental Protection Administration; Council for Economic Planning and Development; National Science Council; Council of Agriculture; Science & Technology Advisory Group (STAG); Committee for the Development Fund; Department of Industrial Technology, MOEA; Intellectual Property Office, MOEA; and related government agencies; and representatives, academics, and experts from major research organizations and industry to form an inter-agency promotional organization.
The role of the Program Office is to serve as a window for the exchange of vital information between domestic and foreign industry, and to aggressively promote investment in Taiwan. In so doing, the Program Office hopes to accelerate the upgrading of Taiwan’s biotechnology and pharmaceutical industries and promote Taiwan to become an R&D, manufacturing and operations center for the Asia Pacific region, and furthermore to forge ahead to establish a global operations center.
Could you please give our readers an overview of the importance of Taiwan for Celgene in a regional and a global context? What is attractive in Taiwan for Celgene? Celgene…
Novo Nordisk is one of the few pharmaceutical multinationals focused in one key therapeutic area. Perhaps you could start by telling our readers about how diabetes has evolved in Taiwan…
Please tell our readers about the importance of GSK Taiwan within the context of the company’s global operations, and also what there is in Taiwan that makes it so attractive…
Medigen was created in 1999 and is a listed company. How did the vision for the company come about, and what was it that attracted today’s main shareholders to Medigen?…
Please describe the activities of the IRPMA to our readers, and explain the membership advantages of your association. Today the IRPMA consists of 37 multinational research-based pharmaceutical manufacturers, as well…
The Development Centre for Biotechnology was founded in 1984 as a tool for connecting biotechnological academia to the Taiwanese industry and promoting the strengths of Taiwan’s biopharmaceutical sector to the…
Please explain the factors that led to the creation of the Taiwan Intellectual Property Office, and its main activities today. For the Taiwanese government, intellectual property (IP) rights are very…
Genovate was founded in 1995. It is a very interesting story: a mix of biotech, the history with American company Genelabs, government investments and also private investment through Chinachem. Can…
See our Cookie Privacy Policy Here